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ABSTRACT: A series of N6-substituted-5′-C-(2-ethyl-2H-tetrazol-5-yl)-adenosine and 2-chloro-adenosine derivatives was
synthesized as novel, highly potent dual acting hA1AR agonists and hA3AR antagonists, potentially useful in the treatment of
glaucoma and other diseases. The best aﬃnity and selectivity proﬁles were achieved by N6-substitution with a 2-ﬂuoro-4-chloro-
phenyl- or a methyl- group. Through an in silico receptor-driven approach, the molecular bases of the hA1- and hA3AR
recognition and activation of this series of 5′-C-ethyl-tetrazolyl derivatives were explained.
■ INTRODUCTION
Adenosine receptors (ARs) belong to the G protein-coupled
receptor (GPCR) family, with A1AR and A3AR coupled to Gi,
and A2A and A2B coupled to Gs.
1 The A1 adenosine receptor
(A1AR) is the best characterized subtype of the four known
ARs and the most conserved AR subtype among species.1
Selective A1AR agonists have antiarrhythmic, antinociceptive,
and neuro- and cardioprotective eﬀects. Moreover, A1AR
agonists reduce lipolysis in adipose tissue and reduce elevated
intraocular pressure (IOP), the most widely recognized risk
factor for the onset and progression of glaucoma.2 The A3AR is
the most recently identiﬁed AR subtype and is involved in a
variety of physiological and pathophysiological processes.1
A3AR agonists are useful in several autoimmune inﬂammatory
conditions such as arthritis, psoriasis, and inﬂammatory bowel
disease.3 Instead, A3AR antagonists may be beneﬁcial in the
treatment of glaucoma4 and respiratory tract diseases such as
asthma.5 Recent ﬁndings indicated that some compounds might
act through two diﬀerent subtypes of a receptor family, with
both pathways leading to beneﬁcial eﬀects. A dual A2BAR and
A3AR antagonist was developed by Novartis as an antiasthmatic
agent,6 while GlaxoSmithKline has investigated a dual A2AAR
agonist and A3AR antagonist as anti-inﬂammatory agent.
7 More
recently, Jacobson et al.8 reported dual acting human (h)
A2AAR agonists and hA3AR antagonists that might be
advantageous for asthma or other inﬂammatory diseases. To
date, no examples of dual acting hA1AR agonists and hA3AR
antagonists are known. Only a combination of INO-8879, a
potent A1AR agonist in phase I/II of clinical trials for the
treatment of glaucoma, with an A3AR antagonist, was claimed
in WO2010127210 A1.9 Therefore, the availability of dual
acting hA1AR full agonists and hA3AR antagonists may be of
great interest in the treatment of some pathological conditions
such as glaucoma. Selectivity for the A1AR may be achieved by
substitution of the N6-position of adenosine with a wide range
of cycloalkyl-, bicycloalkyl-, and arylalkyl groups.10 Moreover,
modiﬁcations at the ribose moiety, serving as a recognition
domain of A1 receptors, contributes to A1AR aﬃnity, selectivity,
and eﬃcacy, leading to full or partial A1 agonists.
11 Our
previous work showed that replacement of the 5′-hydroxy
group by a chlorine atom in N6-substituted adenosine
derivatives increased selectivity for A1AR.
12 5′-Chloro-5′-
deoxy-N6-(±)-(endo-norborn-2-yl)-adenosine (5′Cl5′d-
(±)-ENBA) displayed high A1AR aﬃnity and selectivity. It
was shown to reduce both mechanical allodynia and thermal
hyperalgesia in a mice model of neuropathic pain without
aﬀecting motor and cardiovascular functions13 and to reduce
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dyskinesia evoked by L-DOPA in a mice model of Parkinson’s
disease.14 Structure−activity relationships of A3AR, extensively
reviewed by Jacobson et al.,15 have pointed out that potent and
selective A3AR agonists were obtained by combining sterically
bulky N6 groups with a 5′-uronamide moiety on the ribose.
However, a smaller N6-methyl group also maintained hA3AR
binding aﬃnity with the beneﬁcial eﬀect of more favorable
physicochemical properties that are predictive of greater drug-
like properties in vivo.16 At the ribose moiety, the removal of
the ability of a 5′-N-alkyluronamide to donate an H-bond (e.g.,
through a N,N-dimethylation) or the complete removal of
substituents at the 4′-position (e.g., truncated adenosine
derivatives) switched the eﬃcacy from hA3AR agonists to
hA3AR antagonists.
17,18 On the basis of these ﬁndings and as a
proof of the concept, we designed and synthesized a new series
of N6-substituted-5′-C-(2-ethyl-tetrazol-5-yl)-adenosine and 2-
chloro-adenosine derivatives (compounds 3−13) as highly
potent dual acting hA1AR agonists and hA3AR antagonists. 5′-
C-(2-ethyl-2H-tetrazol-5-yl)-adenosine (1) and 2-chloro ana-
logue 2 were also synthesized. The latter (2) has been reported
already as intermediate in the synthesis of hA2AAR agonists,
19
but no biological studies were provided. Compounds 1−13
were evaluated for aﬃnity, selectivity, and eﬃcacy at all cloned
human adenosine receptor subtypes. Finally, an in silico
receptor-driven approach was used to gain insight into the
structural basis for AR recognition and activation in this series
of 5′-C-ethyl-tetrazolyl derivatives.
■ RESULTS AND DISCUSSION
Chemistry. The 5′-C-ethyl-tetrazolyl adenosine derivatives
1−13 were synthesized starting from 2-ethyl-5-(1,2,3-tri-O-
acetyl-D-ribofuranosyl)-2H-tetrazole (14, mixture of α and β
anomers) as described in Scheme 1. Compound 14 was
synthesized following the method described in the literature.19
Coupling of 14 with 6-chloropurine (15) or 2,6-dichloropurine
(16) was performed by trimethylsilyl triﬂuoromethanesulfonate
(TMSiOTf) mediated N-glycosylation in acetonitrile and in the
presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to
obtain the protected compounds 17 and 18,19 respectively, in
high yields. The synthesis of derivatives 17 and 18 resulted in a
stereoselective ribosylation (β/α, 99:1). Nucleophilic displace-
ment of a 6-chlorine atom in 17 and 18 by ammonia or the
appropriate amine, followed by deprotection, furnished the
nucleoside analogues 1−13. Assignment of the β-anomeric
conﬁguration of nucleosides 1−13 was performed by proton
NOE data. In particular, the β-anomeric conﬁguration was
determined by selective irradiation of the H-1′ signal that
increased the intensity of the H-4′ signal; this indicates that H-
1′ and H-4′ are located on the same face of the ribosyl ring.11
Binding Aﬃnity. All the synthesized compounds (1−13)
were tested in radioligand binding assays for aﬃnity at the
human recombinant adenosine receptors, stably transfected
into Chinese hamster ovary (CHO) cells, utilizing radio-
ligandbinding assays (A1, A2A, and A3) or an adenylyl cyclase
activity assay (A2B),
20,21 and the results are reported in Tables 1
and 2. As shown in Table 1, all compounds bearing in the N6
position a substituent such as cyclopentyl (5, 6), endo-
(±)-norbornyl (7, 8), tetrahydrofuran-2-yl (9, 10), and 2-
ﬂuoro-4-chloro-phenyl (11, 12) displayed Ki values ranging
from 0.31 to 1.67 nM at hA1AR, with 6 as the most potent one.
However, the replacement of the 5′-hydroxy-methyl group in
N6-substituted adenosine derivatives with the 2-ethyl-2H-
tetrazol-5-yl one provided also potent hA3AR ligands (5−12)
with Ki values in the low nanomolar range (Ki = 2.61−16.1
nM). As expected, substitution in N6 position with a 3-iodo-
benzyl- or a methyl- group increased hA3AR aﬃnity and
reduced hA1AR aﬃnity. 3, 4, and 13 displayed hA3AR aﬃnities
in the subnanomolar range (Ki = 0.43−0.59 nM) and hA1AR
aﬃnities in the low nanomolar range (Ki = 2.39−8.59 nM). It is
interesting to note that replacing the 5′-hydroxymethyl in
adenosine derivatives with the 5′-C-(2-ethyl)-2H-tetrazol-5-yl
group, high aﬃnities at both hA1 and hA3AR were maintained,
even without N6 substitution (1 and 2, Ki = 0.92 and 0.97 nM
at hA1AR, and 3.86 and 1.80 nM at hA3AR, respectively).
Unexpectedly, adenosine derivatives 1 and 2 showed a binding
aﬃnity in the low nanomolar range, also at hA2AAR, resulting in
potent but nonselective human adenosine receptor ligands. It is
noteworthy that 2-substituted derivatives of 1 and 2 have been
previously reported as potent and selective A2AAR agonists.
19
Our results showed that the omission of the 2-amino-alcohol or
its substitution with a chlorine in the 5′-C-ethyl-tetrazolyl-
adenosine derivatives maintained A2AAR aﬃnity and restored
A1AR and A3AR aﬃnities (Table 1). The introduction of a
chlorine atom in the 2-position of the adenine ring resulted in a
2.2-fold increase in hA1AR aﬃnity of N
6-cyclopentyl adenosine
derivatives (e.g., 6 vs 5), but not of N6-endo-norbornyl (8 vs 7),
N6-tetrahydrofuranyl- (10 vs 9), and N6-(2-ﬂuoro-4-chloro-
phenyl)-adenosine derivatives (12 vs 11). A1AR aﬃnity does
not seem to be deeply inﬂuenced by N6-substitution in the 5′-
C-ethyl-tetrazolyl-adenosine derivatives because unsubstituted
compounds 1 and 2 showed high hA1AR aﬃnity (Ki = 0.92 and
0.97 nM, respectively) and behaved as hA1AR full agonists
(EC50 = 26.3 and 19.8 nM, respectively). However, N
6-
substitution with a cyclopentyl (5, 6), endo-(±)-norbornyl (7,
8), or 2-ﬂuoro-4-chloro-phenyl (11) group provided hA1AR
agonists more potent than 1 and 2, with 6 as the most potent
hA1AR agonist of the series (Ki = 0.31 nM). Analogously, N
6-
substitution with a methyl (3, 4) or a 3-iodo-benzyl (13) group
decreased hA1AR and hA2AAR aﬃnities and increased hA3AR
aﬃnity, resulting in 4 as the most potent hA3AR ligand (Ki =
0.43 nM) of the series. Very interestingly, as shown in the
adenylyl cyclase assay (Table 2), all tested compounds behaved
as hA3AR antagonists. 3, 4 and 13 resulted the most potent,
with EC50 values of 6.38, 7.69, and 13.3 nM, respectively. 3, 4,
11, and 12 showed the best selectivity and aﬃnity proﬁle at
both hA1AR and hA3AR, resulting in the ﬁrst very potent and
selective dual acting hA1AR agonists and hA3AR antagonists
(for selectivities see Supporting Information (SI), Table S1). It
is noteworthy that 4 presented the highest selectivity toward
A2A (390 and 7800, respectively).
Scheme 1. Synthesis of Target Compounds 1−13
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Adenylyl Cyclase Activity. All novel compounds were
tested in a functional A2B receptor assay and some showed a
moderate potency in stimulation of adenylyl cyclase activity.
The most active was 1 (EC50 = 347 nM), while the least active
was 8 (EC50 >30000 nM). It is noteworthy that 4 and 13
behaved as a partial A2B agonist, whereas all other compounds
showing measurable potency presented as full agonists (Table
2). All compounds were additionally tested for their functional
eﬀect on human A1, A2A, and A3 receptors by determination of
adenylyl cyclase activity. As expected, all tested compounds
were found to be agonists at A1, and A2A receptors, whereas
they were antagonists at the A3 subtype (Table 2, Figure 1).
Interestingly, only compound 13 was found to be a partial
agonist at A2AAR. 5−11 showed EC50 values at hA1AR ranging
from 3.62 to 10.2 nM, whereas the most potent hA3AR
antagonists 3, 4, and 13 displayed EC50 values at hA3AR
ranging from 6.38 to 13.3 nM. Among the tested compounds,
the best EC50 values at A2AAR were displayed by 1 (2.36 nM),
2 (3.84 nM), 6 (5.31 nM), 7 (7.71 nM), and 11 (8.04 nM).
Molecular Modeling. To explain the observed binding
data from a molecular point of view, we performed a receptor-
based molecular modeling study of the potent dual acting
hA1AR and hA3AR ligands 6 and 13. Previously reported
homology models of the hA1-
22 and hA3ARs,
23 built using the
agonist-bound A2AAR (PDB: 3QAK)
24 and the antagonist-
bound A2AAR (PDB: 3UZC)
25 crystallographic structures as
templates, were used to perform docking simulations of each
compound. Docking was carried out using the GOLD 5.2.2
Table 1. Binding Aﬃnity of 5′-C-Ethyl-tetrazolyl-adenosine Derivatives
Ki (nM)
a




1 H H 0.919 (0.716−1.18) 8.12 (6.01−11.0) 3.86 (3.49−4.28)
2 H Cl 0.966 (0.770−1.21) 20.7 (16.9−25.3) 1.80 (1.42−2.29)
3 CH3 H 3.56 (3.02−4.19) 778 (685−883) 0.478 (0.421−0.541)
4 CH3 Cl 8.59 (8.11−9.10) 3350 (2920−3840) 0.429 (0.361−0.509)
5 cyclopentyl H 0.682 (0.425−1.09) 93.0 (74.4−116) 7.97 (4.68−13.6)
6 cyclopentyl Cl 0.311 (0.285−0.340) 62.2 (44.2−87.3) 3.90 (3.42−4.46)
7 (±)-endo-2-norbornyl H 0.453 (0.336−0.610) 64.5 (44.3−94.0) 8.85 (7.87−10.0)
8 (±)-endo-2-norbornyl Cl 0.728 (0.616−0.860) 164.0 (128−211) 16.1 (11.6−22.4)
9 tetrahydrofuranyl H 1.23 (0.946−1.60) 554 (484−634) 15.4 (12.2−19.5)
10 tetrahydrofuranyl Cl 1.06 (0.737−1.52) 870 (777−974) 9.62 (6.54−14.1)
11 2-ﬂuoro-4-chloro-phenyl H 0.432 (0.330−0.565) 77.5 (69.4−86.6) 2.61 (1.84−3.71)
12 2-ﬂuoro-4-chloro-phenyl Cl 1.67 (1.42−1.97) 223 (206−241) 4.71 (3.49−6.36)
13 2-iodo-benzyl Cl 2.39 (2.18−2.62) 108 (68.5−171) 0.588 (0.540−0.641)
aKi values are given in nM with 95% conﬁdence intervals in parentheses.
bDisplacement of speciﬁc [3H]CCPA binding in CHO cells transfected
with the human recombinant A1 adenosine receptor.
cDisplacement of speciﬁc [3H]NECA binding in CHO cells transfected with human
recombinant A2A adenosine receptor.
dDisplacement of speciﬁc [3H]HEMADO binding in CHO cells transfected with human recombinant A3
adenosine receptor.
Table 2. EC50 Values for Adenylyl Cyclase Activation (A2A and A2B) or Inhibition (A1 and A3)
a
EC50 (nM)
compd R R1 A1 A2A A2B A3
1 H H 26.3 (20.8−33.3) 2.36 (2.00−2.78) 347 (266−454) 93.6 (79.7−110)
2 H Cl 19.8 (14.3−27.5) 3.84 (3.32−4.44) 542 (340−865) 31.7 (23.2−43.2)
3 CH3 H 97.2 (84.4−112) 1710 (1150−2530) 1480 (923−2390) 6.38 (5.03−8.07)
4 CH3 Cl 250 (204−307) 238 (206−274) 3510 (2290−5360) pag (75%) 7.69 (6.34−9.32)
5 cyclopentyl H 8.61 (6.68−11.1) 9.75 (6.42−14.8) 675 (528−862) 51.5 (29.9−88.6)
6 cyclopentyl Cl 3.62 (3.31−3.96) 5.31 (3.96−7.13) 1150 (820−1620) 39.5 (33.0−47.3)
7 (±)-endo-2-norbornyl H 4.66 (3.33−6.54) 7.71 (6.76−8.80) 1,010 (675−1510) 83.9 (45.9−153)
8 (±)-endo-2-norbornyl Cl 10.2 (8.97−11.5) 12.8 (9.41−17.4) >30000 721 (637−816)
9 tetrahydrofuranyl H 8.74 (7.24−10.5) 25.1 (19.8−31.9) 1340 (716−2510) 61.9 (53.6−71.4)
10 tetrahydrofuranyl Cl 7.42 (4.38−12.6) 33.2 (28.7−38.4) 3150 (1780−5560) 104 (67.0−162)
11 2-ﬂuoro-4-chloro-phenyl H 10.2 (9.48−11.1) 8.40 (7.41−9.53) 530 (314−896) 33.9 (21.1−54.5)
12 2-ﬂuoro-4-chloro-phenyl Cl 64.8 (47.9−87.8) 28.8 (20.8−39.9) 1110 (888−1400) 37.0 (27.1−50.7)
13 2-iodo-benzyl Cl 64.9 (54.2−77.8) 9.04 (6.37−12.8) pag (75%) 834 (563−1230) pag (76%) 13.3 (6.72−26.5)
aAll tested compounds are full agonists at the A1, A2A, and A2B receptors (eﬃcacy ≥90%, unless stated otherwise). All tested compounds are
antagonists at the A3 receptor. pag, partial agonist (% eﬃcacy).
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program26 in combination with the ChemPLP27 scoring
function (rescoring with ChemScore).28 A docking pose of 6
and 13 inside both the hA1AR and hA3AR binding sites (Figure
2) featured most of the main receptor−ligand interactions
observed in the agonist-bound hA2AAR crystal structures.
24,29
These interactions, shown as 2D diagrams (see SI, Figure S1),
involved both the adenine core and the ribose ring. In
particular, the 3′- and 2′-OH groups formed H-bonds with
residues (numbers in parentheses follow the Ballesteros−
Weinstein notation)30 at positions 7.42 (T277 in hA1AR and
S271 in hA3AR) and 7.43 (H278 in hA1AR and H272 in
hA3AR), respectively. The side chain of N6.55 (N254 in
hA1AR and N250 in hA3AR) strongly interacted with these
compounds through two H-bonds, including the 6-NH group
and the N7 atom of the adenine ring. It is noteworthy that in
hA3AR, only the 6-NH group and not the N7 atom of the
adenine ring was in contact with the N250 side chain.
Moreover, the adenine ring was anchored inside the binding
site by a π−π stacking interaction with a phenylalanine in EL2
(F171 in hA1AR and F168 in hA3AR) and strong hydrophobic
contacts with leucine 6.51 (L250 in hA1AR and L246 in
hA3AR) and isoleucine 7.39 (I274 in hA1AR and I268 in
hA3AR). Two key interactions observed in the hA2AAR X-ray
structures between T88 (3.36) and H250 (6.52) and the 5′-
CO-NH-alkyl groups of the cocrystallized agonists NECA and
UK-43209724,29 were maintained at the hA1AR binding site by
these 5′-C-ethyl-tetrazolyl nucleosides, while they were absent
in the hA3AR binding site. In particular, in the hA1AR, the N1
and N3 nitrogens of the 5′-C-tetrazole ring of ligands were able
to accept H-bonds by T913.36 OH and H2516.52 NH hydrogens,
respectively. In the case of hA3AR, the H
6.52 residue is replaced
with a shorter serine (S2476.52), which allows the 5′-C-tetrazole
ring to adopt a 180° ﬂipped-ring orientation with the 2-ethyl
substituent pointing toward S247. Consequently, the N3 and
N4 sp2 lone pairs lying in the plane of tetrazole ring were
oriented too far away from the T943.36 OH group to accept an
eﬀective H-bond. Therefore, it can be hypothesized that the
replacement of H6.52 in hA1AR with a serine in hA3AR and the
lack of H-bonds with T943.36 is related to the diﬀerent eﬃcacy
proﬁle of the 5′-C-ethyl-tetrazolyl nucleosides at hA1 and
hA3ARs. This is in line with the previous results of Tosh et al.,
22
who demonstrated that the missing interaction between 4′-
truncated nucleosides and T943.36 was related to the lack of
receptor activation, indicative of antagonist behavior. Fur-
thermore, the hydrophilic ribose-binding region is critical for
activation that likely entails essential residues of TM3, TM6,
and TM7 throughout the AR family, as in the hA2AAR.
24,29
Multiple H-bonding groups in this region promote agonism at
the hA3AR,
31 such as the interactions of the 5′-CH2OH of the
ribose moiety or the corresponding 5′-CO-NH-alkyl in NECA-
like analogues. Thus, loss of the crucial interaction between the
5′-C-ethyl-tetrazolyl substituent and T943.36 is expected to
reduce AR eﬃcacy, which it clearly does at the hA3AR. It
should also be noted that the residue at position 3.32 (L90) in
hA3AR is a nonconserved hydrophobic and bulky leucine,
whereas a smaller valine (V87) is present in the other AR
subtypes. Residue 3.32 was near the ribose ring of the docked
compounds in both hA1AR and hA3AR binding cavities. The
Figure 1. Eﬀect of selected compounds on activity of adenylyl cyclase. 3, 4, 11, and 12 mediate an inhibition of forskolin-stimulated adenylyl cyclase
activity via A1 adenosine receptors (A). They show the same inhibition as the full agonist CCPA (not shown). The A2A-mediated stimulation by
these four compounds shown in (B) reaches the level of stimulation with NECA (100%) and thus documents that they act as full agonists at the A2A
receptor as well. In contrast, all four compounds present as antagonists at the A3 receptor. They fully reverse the NECA-induced inhibition of
forskolin-stimulated adenylyl cyclase activity (C).
Figure 2. Putative binding modes of selected 5′-C-ethyl-tetrazolyl derivatives 6 (slate carbons) and 13 (orange carbons) obtained after docking
simulations at the hA1AR (A, cyan ribbons) and hA3AR (B, green ribbons) models. Poses are viewed from the membrane side. Ligands and
interacting key residues (gray) are represented as stick models. The critical amino acids important for ligand recognition are labeled in red. H-
bonding interactions are pictured as dotted black lines. (C) Superimposition of the binding modes of 13 into both hA1AR and hA3AR binding
pockets. For clarity, only side chain atoms of some residues are shown. Amino acid variations in the ligand binding pocket between hA1AR and
hA3AR subtypes are shown with cyan and green coloring, respectively.
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longer side chain of L903.32 in hA3AR compared to V87
3.32 of
hA1AR, together with the lack of interactions with T94
3.36,
could negatively aﬀect the ability to fully activate the receptor
through conformational aﬀects at TM3, TM6, and TM7 caused
by the binding of the 5′-C-ethyl-tetrazolyl derivatives. The
structural basis for the full agonism of 6 at hA1AR might be
related to some interactions formed by the N6 group at the
entrance of the binding site that are important in orienting and
stabilizing the compound within the pocket. As shown in Figure
3A, the N6-cyclopentyl substituent of 6 and the 2-iodo-benzyl
substituent of 13 occupied a small hydrophobic pocket,
designated “subpocket B” by Tosh et al.,32 which is located
between TM6 and TM7 and lined by residues L253 (6.54),
T257 (6.58), T270 (7.35), and at the bottom by L250 (6.51).
An optimal occupancy of this pocket by compounds with a
sterically more bulky substituent at the N6-position seems to be
required for increased aﬃnity at this receptor subtype (compare
5−12 and methyl-substituted compounds 3 and 4 in Table 1).
The hA1AR and hA3AR diﬀer in the nature of the residues
delimiting this pocket, which could explain the diﬀerent aﬃnity
proﬁles of the 5′-C-ethyl-tetrazolyl derivatives at these
receptors. In particular, the three residues lining the hydro-
phobic pocket in the hA1AR are replaced in the hA3AR by
bulkier side chains I249 (6.54), I253 (6.58), and L264 (7.35).
Thus, the steric restriction of this pocket between TM6 and
TM7 (Figure 3B) can be the reason for the decreased aﬃnity at
hA3AR of 5−12 bearing larger N6-substituents, as they are too
bulky to ﬁt in the pocket. On the other hand, if an extended
and more ﬂexible group (e.g., 2-iodobenzyl) is present at the
N6-position, then the substituent slightly shifts within the
hA3AR binding site pointing toward TM5, TM6, and EL2
(Figure 3B), and so it establishes hydrophobic interactions with
V169 (EL2), M172 (EL2), M174 (5.35), M177 (5.38), and
I253 (6.58). This ﬁnding can explain the enhanced hA3AR
aﬃnity of 13. As shown in Table 1, the N6-unsubstituted
compounds (1, 2) have greater aﬃnity at the hA1AR than the
N6-methyl compounds (3, 4), while the converse is true at the
hA3AR. The diﬀerence in the behavior of these compounds
between the two receptor subtypes seems to be related to the
fact that at the hA1AR the exocyclic amino groups of 1 and 2
make two polar interactions with residues N2546.55 (H6) and
E1725.30 (EL2). These polar interactions contribute to the
binding energy and seem to be a major selectivity factor that
distinguishes hA1AR and hA2AAR from the hA3AR subtype. In
fact, in this last subtype, a valine residue (V169) takes the place
of E1725.30 and the above-mentioned stabilizing interaction is
lost, thus decreasing the binding aﬃnity of 1 and 2 for hA3AR.
The interaction of E5.30 toward the adenine primary amine has
been conﬁrmed by the recently published structure of the
A2AAR cocrystallized with the two agonists adenosine and
NECA.29 Obviously, a small alkyl chain at the N6-position, such
as a methyl group, prevents the secondary amine from
interacting with the E1725.30 side chain because the only
available hydrogen atom is already engaged in an H-bonding
interaction with N2546.55, and this explains the lower aﬃnity of
3 and 4 at hA1AR. In contrast, at hA3AR, the N
6-methyl groups
of 3 and 4 were involved in a stabilizing hydrophobic
interaction with V169 (EL2), which is missing at hA1AR
because this amino acid is replaced by the polar residue E172. It
appears that this is why 3 and 4 maintain their binding aﬃnity
at hA3AR but reduce it at hA1AR.
■ CONCLUSIONS
In summary, a series of N6-substituted-5′-C-(2-ethyl-2H-
tetrazol-5-yl)-adenosine and 2-chloro-adenosine derivatives
were synthesized in order to study the structure−activity
relationships of this class of nucleosides. We reported for the
ﬁrst time that N6-substituted-5′-C-(2-ethyl-2H-tetrazol-5-yl)-
adenosine derivatives acted as potent dual hA1AR full agonists
and hA3AR antagonists. The combination of 5′-C-ethyl-
tetrazolyl with the appropriate N6-substitution in adenosine
derivatives provides improved aﬃnity for both hA1AR and
hA3AR. A methyl or a 3-iodo-benzyl group at the N
6 position of
5′-C-2-ethyl-2H-tetrazolyl-adenosine derivatives were beneﬁcial
for high binding aﬃnity at the hA3AR, whereas a cycloalkyl-,
bicycloalkyl- or an aryl group conferred subnanomolar aﬃnity
for hA1AR. Unexpectedly, an unsubstituted amino group at the
N6 position of 5′-C-2-ethyl-2H-tetrazolyl-adenosine derivatives
(1, 2), maintains subnanomolar A1AR and low nanomolar
A3AR aﬃnities. Additionally, 1 and 2 displayed signiﬁcant
binding aﬃnity also at the hA2AAR, resulting in nonselective
ligands. A molecular modeling study fully rationalized the
mixed activity of these novel dual hA1AR agonists and hA3AR
antagonists. This feature might be advantageous for the
treatment of glaucoma and other diseases (e.g., epilepsy).
■ EXPERIMENTAL SECTION
Chemistry. All compounds were analyzed by 1H and 13C NMR,
and MASS. The purity of ﬁnal compounds was ≥95% as measured by
combustion analysis and HPLC. Full experimental procedures can be
found in the SI.
Analytical Data for (2R,3S,4R,5R)-2-(2-Ethyl-2H-tetrazol-5-yl)-5-
(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol (3). Yield
86%. 1H NMR (400 MHz, DMSO-d6): δ 1.47 (t, J = 7.3 Hz, 3H,
CH2CH3), 2.91 (brs, 3H, CH3), 4.53−4.59 (m, 1H, H-4′), 4.72 (q, J =
7.3 Hz, 2H, CH2CH3), 4.81 (q, J = 5.3 Hz, 1H, H-3′), 5.18 (d, J = 4.3
Hz, 1H, H-5′), 5.75 (d, J = 5.5 Hz, 1H, OH), 5.83 (d, J = 5.6 Hz, 1H,
Figure 3. Top view of the docking pose of 6 (slate carbons) and 13 (orange carbons) inside the binding site of the hA1AR (A, cyan ribbons) and
hA3AR (B, green ribbons) models. A gray Connolly surface of amino acids at the entrance of the binding site is displayed.
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OH), 6.10 (d, J = 4.7 Hz, 1H, H-2′), 7.78 (brs, 1H, NH), 8.11 (s, 1H,
H-2), 8.38 (s, 1H, H-8). 13C NMR (400 MHz, DMSO-d6): δ 14.21,
28.32, 48.38, 73.55, 73.79, 77.49, 87.84, 118.31, 138.92, 151.05,
153.74, 156.78, 164.26 ppm. MS (API-ESI): m/z 334.13 [M + H]+.
Anal. Calcd for (C13H17N9O3) C, 44.95; H, 4.93; N, 36.29. Found: C,
44.92; H, 4.89; N, 36.31. HPLC purity: tR = 3.37, 99.81%
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